t*******r
发帖数: 364 | 1 The active substance in Lenvima, lenvatinib, is a tyrosine-kinase inhibitor.
This means that it blocks the activity of enzymes known as tyrosine kinases
. These enzymes can be found in certain receptors (such as VEGF, FGFR and
RET receptors) in cancer cells, where they activate several processes
including cell division and the growth of new blood vessels. By blocking
these enzymes, lenvatinib can block the formation of new blood vessels and
hence cut off the blood supply that keeps cancer cells growing, and reduce
their growth. Lenvatinib may also alter the activity of the immune system (
the body’s natural defences)
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the
kinase activities of vascular endothelial growth factor (VEGF) receptors
VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits
other RTKs that have been implicated in pathogenic angiogenesis, tumor
growth, and cancer progression in addition to their normal cellular
functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3,
and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and
RET. |
|
